Skip to content

Clinical study for analyzing the SUV threshold value of the regions of interest containing the range of reactive morphological cells containing tumor cells through C11-Acetate PET in brain tumor patients.

Clinical study for analyzing the SUV threshold value of the regions of interest containing the range of reactive morphological cells containing tumor cells through C11-Acetate PET in brain tumor patients.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0008555
Enrollment
33
Registered
2023-06-23
Start date
2023-06-09
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Yonsei University Health System, Severance Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Adult men and women aged 20 and above Patients with newly diagnosed primary brain tumors Brain tumors that show enhancement in MRI and are similar in appearance to the characteristic shape of glioblastoma.

Exclusion criteria

Exclusion criteria: Patients who have received chemotherapy or radiation therapy as previous treatments Cases where the participant is unable to read the consent form (e.g., illiteracy, foreigners, etc.)

Design outcomes

Primary

MeasureTime frame
This study aims to analyze the tissues that show C11-Acetate uptake during brain tumor surgery, determine the range of reactive astrocytes containing tumor cells according to the degree of C11-Acetate uptake, and establish the most ideal cutoff for Acetate uptake for this purpose.

Secondary

MeasureTime frame
The volume of C11-Acetate uptake and the prognosis of the patient.

Countries

Korea, Republic of

Contacts

Public ContactDongwoo Kim

Yonsei University Health System, Severance Hospital

kdwoo@yuhs.ac+82-2-2228-4852

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026